Abstracts over the follow-up period. After matching, there was no significant difference in health services utilization between drug groups. However, risperidone subjects had significantly lower pharmacy costs (<.0001) and total costs (p = 0.0181) compared to olanzapine subjects. Subjects with affective disorders had total costs that were significantly higher compared to subjects with schizophrenia or childhood disorders. CONCLUSIONS: Studies comparing cost and utilization among atypical antipsychotics should consider the host of factors that may influence receipt or regiment of care such as diagnostic condition, duration of therapy and dosing.
1
Analysis Group/Economics, Boston, MA, USA; 2 Harvard University, Boston, MA, USA; 3 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: The economic burden of depression was estimated at approximately $44 billion in 1990. A subsequent study refined the estimation of the morbidity costs associated with depressive disorders and revised this figure to $53 billion. The objective of this study is to provide a 10-year update of the economic burden of depression using the same refined methodology. METHODS: Using a human capital approach we developed prevalence-based estimates of 3 major cost categories: 1) direct costs, 2) mortality costs arising from depression-related suicides, and (3) morbidity costs associated with workplace depression. Estimates were updated to reflect 2000 values, using the most current epidemiological data for prevalence rates and publicly available cost data by condition. RESULTS: We estimate that the total economic burden of depression in 2000 was $81.5 billion. Of this total, $26.1 billion-32%-are direct medical costs, $5.4 billion-7%-are mortality costs, and $49.9 billion-61%-are morbidity costs. Work absenteeism resulted in $34.5 billion-42% of total costs, while work cutback costs were $15.4 billion-19% of total costs. CONCLUSIONS: The economic burden of depression was $81.5 billion in 2000. Morbidity generated the largest portion, 61%, of these costs. Future research investigations will incorporate additional costs associated with depressive disorders, including the excess costs of treating comorbid illnesses and the cost burden of depressed individuals' family members.
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A STUDY OF THE ECONOMIC BURDEN OF DEPRESSION
Trivedi DN, Bollu V, Lawrence L The University of Louisiana at Monroe, Monroe, LA, USA OBJECTIVES: Depression is a major public health issue in the United States. It is associated with high morbidity and mortality. Hence it is important to evaluate its economic impact on the U.S. health care system. Information about the economic burden of depression will help in effective utilization and allocation of healthcare resources. The main outcome measure of this study was the economic burden of depression in a patient population of 703 with a primary diagnosis of depression. METHODS: A secondary database analysis was conducted using the Medical Expenditure Panel Survey, 1999 (MEPS 99) . Patients with primary diagnoses of depression were identified using International Classification of Diseases, 9th revision, Clinical Modification (ICD 9 CM).
